Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

NCT02345265 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02345265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02345265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 23, 2016
Completion date
March 4, 2027
Enrollment
70 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian carcinoma, ovarian high grade endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, primary peritoneal carcinoma, primary peritoneal endometrioid adenocarcinoma, primary peritoneal serous adenocarcinoma